The letter of intent describes the framework for the collaboration and is a first step on the journey towards reaching a final distribution agreement. EndoDrill GI, which is marketed in both the US and Europe, is designed for the early detection and diagnosis of gastrointestinal cancers such as pancreatic, gastric and esophageal cancers. The instrument stands out for its precision and ability to obtain high-quality tissue samples, which can improve diagnostics for patients.
BiBBInstruments The first sale in the US took place in January UC Davis Health, one of the country's leading university hospitals. Now the company, together with TaeWoong Medical USA a targeted launch in selected hospitals in the fall of 2025, with a broader national rollout in 2026.
– This LOI marks an exciting and important step for BiBB. Following our first sale in the US earlier this year, we are now in a position to accelerate our commercial journey in the world's largest healthcare market, comments BiBBInstruments CEO Fredrik Lindblad. TaeWoong Medical USA is a fast-growing distributor with an innovative portfolio of therapeutic endoscopic ultrasound products, such as stents and RFA equipment, and sees EndoDrill as a natural complement in diagnostic biopsy, making them an ideal partner.
